ENTA
Enanta Pharmaceuticals, Inc.NASDAQHealthcare$13.14+1.31%ClosedMarket Cap: $305.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.24
P/S
4.59
EV/EBITDA
-7.85
DCF Value
$-62.36
FCF Yield
-6.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-109.1%
Net Margin
-106.8%
ROE
-78.6%
ROA
-21.7%
ROIC
-22.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $18.6M | 100.0% | $-11.3M | $-11.9M | $-0.56 | — |
| Q4 2025 | $15.1M | 100.0% | $-18.4M | $-18.7M | $-0.87 | — |
| FY 2025 | $65.3M | 93.0% | $-85.3M | $-81.9M | $-3.84 | — |
| Q3 2025 | $18.3M | 100.0% | $-18.9M | $-18.3M | $-0.86 | — |
| Q2 2025 | $14.9M | 100.0% | $-24.5M | $-22.6M | $-1.06 | — |
| Q1 2025 | $17.0M | 100.0% | $-23.5M | $-22.3M | $-1.05 | — |
| Q4 2024 | $14.6M | 100.0% | $-29.9M | $-28.8M | $-1.36 | — |
| FY 2024 | $67.6M | 100.0% | $-121.7M | $-116.0M | $-5.48 | — |
| Q3 2024 | $18.0M | 100.0% | $-24.2M | $-22.7M | $-1.07 | — |
| Q2 2024 | $17.1M | 100.0% | $-32.8M | $-31.2M | $-1.47 | — |
| Q1 2024 | $18.0M | 100.0% | $-34.9M | $-33.4M | $-1.58 | — |
| Q4 2023 | $18.9M | 100.0% | $-31.0M | $-28.1M | $-1.33 | — |